Table 1.
Characteristics of both groups at baseline
| Characteristic | P group (n=45) | O group (n=46) | P-value |
|---|---|---|---|
| Age (years)a | 62.3±11.2 | 63.6±10.5 | 0.567 |
| Genderb | 25/20 | 28/18 | 0.457 |
| Weight (kg)a | 58.4±8.5 | 59.2±9.4 | 0.854 |
| Herpes zoster site | |||
| Intercostal region | 30 | 35 | 0.834 |
| Neck and arm region | 3 | 5 | 0.823 |
| Face region | 8 | 6 | 0.754 |
| Lumbosacral region | 4 | 5 | 0.678 |
| Duration of PHN (months)a | 2.8±1.5 | 2.9±1.6 | 0.821 |
| Cardiac diseaseb | 24/45 | 25/46 | 0.659 |
| Pulmonary diseaseb | 26/45 | 24/46 | 0.547 |
| Liver and renal diseasesb | 8/45 | 8/46 | 0.625 |
| Metabolism and nutrition disordersb | 6/45 | 7/46 | 0.689 |
Notes: Data are presented as mean ± SD or n. P group = pharmacological therapy group; O group = ozone therapy group. P<0.05 was considered statistically significant.
a
Independent-samples t-test.
b
Chi-square test.
Abbreviation: PHN, postherpetic neuralgia.